Skip to main content
Premium Trial:

Request an Annual Quote

Grail: Mostafa Ronaghi

Mostafa Ronaghi has joined Grail's board of directors. Ronaghi is currently Illumina's senior vice president of entrepreneurial development, and previously served as the company's senior VP and chief technology officer, a role in which he led internal research and technology and cofounded Grail. He also cofounded the Illumina Accelerator.

In 2007, Ronaghi cofounded Avantome, a privately held sequencing company that was acquired by Illumina in 2008. Before this, he cofounded NextBio, a search engine for life science data that was acquired by Illumina in 2013. In 2001, Ronaghi cofounded ParAllele Bioscience, which was eventually acquired by Affymetrix, and was involved in the development and commercialization of highly multiplexed technology for genetic testing. In 1997 he cofounded Pyrosequencing AB, which was renamed Biotage in 2003. Ronaghi earned his PhD from the Royal Institute of Technology in Sweden and was a principal investigator at Stanford University from 2002 until 2008, focused on the development of novel tools for molecular diagnostic applications. He also serves on the board of directors of BaseHealth and Clear Labs. 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.